RCKT - Rocket Pharma Debt to Book Capitalization Ratio

Brandmark of Rocket Pharmaceuticals, Inc. (RCKT)

The Rocket Pharmaceuticals (RCKT) sector operates in an autonomous cycle independent of global economic fluctuations, rendering it a resilient asset. Rocket Pharmaceuticals focuses on treating blood and heart pathologies, receiving payments from insurance funds and government agencies, with the indicator standing at 0.07. This daily price action, visualized for analytical convenience, confirms the business status as a closed bioplatform with unique patent protection.

Rocket Corp (RCKT) - Debts to Book Value from 07/04/2022 to 10/27/2026

Metric breakdowns and analytics for Rocket Pharma (RCKT)

- price and consensus price forecast:
Stock Price Rocket Pharmaceuticals|RCKT - Analyst Consensus Forecast
- market capitalization data:
Market Value Rocket Corp|RCKT - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Rocket Pharmaceuticals|RCKT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio rocketpharma.com|RCKT - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Rocket Pharmaceuticals|RCKT - Long-Term Debt to Capital|Short-Term Debt to Capital Rocket Pharmaceuticals Inc|RCKT - Company Cumulative Debt|Debt to Book Value Rocket Corp
Analysis of all company metrics:RCKT Rocket Pharmaceuticals
Product sample of Rocket Pharma

This ratio determines the degree of business dependence on borrowed funds by comparing total liabilities to the amount of equity on the balance sheet. By analyzing the financial leverage chart based on book capitalization, an investor assesses the stability of the financing structure of Rocket Pharmaceuticals (RCKT), which is critical when establishing patent barriers and developing costly gene therapy methods for orphan diseases.

Competitors of Rocket Pharmaceuticals (RCKT)

Debts to Book Capitalization TEM (Tempus AI Inc)|qiagen.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Ionis (IONS)|RGEN: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio RNA|CRISPR (CRSP) - Debts to Book Value|Debts to Book Capitalization WGS|Debt to Book Value RARE|Debt to Book Capitalization Ratio BEAM|Debts to Book Capitalization Sarepta Therapeutics (SRPT)|TWST: Debts to Book Capitalization|TXG - Debts to Book Value|Debt to Book Value Intellia Therapeutics NTLA|stoketherapeutics.com (STOK) - Debt to Book Capital|Debt to Book Value BioLife Solutions BLFS|WVE (Wave Life Sciences Ltd) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Maze Tx MAZE|Debts to Book Capitalization Ratio Sionna Corp|Prime Medicine, Inc. (PRME) - Debts to Book Capitalization|Debt to Net Assets Ratio tayshagtx.com (TSHA)|Debts to Book Capitalization QURE (uniQure)|MeiraGTx Holdings - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regenxbio (RGNX)|SLDB: Debt to Net Assets Ratio|OCGN (Ocugen, Inc.) - Debt to Book Capitalization Ratio|pacb.com (PACB) - Debt to Book Value|BNTC (Benitec Biopharma) - Debts to Book Capitalization|Debts to Book Capitalization Design Therapeutics Inc|Debts to Book Capitalization FDMT (4D Molecular Therapeutics Inc)|Debt to Book Value lexeotx.com (LXEO)|KRRO: Debts to Book Capitalization|EDIT - Debts to Book Value|Silence Therapeutics plc - Debt to Book Value|ProQR Therapeutics N.V. (PRQR) - Debts to Book Capitalization|CDXS - Debt to Book Value|Sangamo BioSciences (SGMO) - Debt to Book Capital|NAUT: Debts to Book Capitalization|Debts to Net Assets metagenomi.co|Debts to Book Capitalization DTIL (Precision BioSciences, Inc.)|Debt to Book Value generationbio.com (GBIO)|Debts to Book Capitalization BOLD (Boundless Bio, Inc)|Exicure Inc. - Debts to Book Capitalization|IMNN - Debt to Book Capitalization Ratio|PHIO: Debt to Book Capitalization Ratio|mustangbio.com - Debt to Book Capitalization Ratio|RNAZ (TransCode Therapeutics, Inc.) - Debts to Net Assets|BNGO - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Applied DNA Corp|Debts to Book Capitalization BLUE (bluebird bio, Inc.)|Debt to Book Value IPA (immunoprecise.com)|Debt to Book Capitalization Ratio OMGA (Omega Therapeutics, Inc.)|OMIC - Debts to Book Capitalization|Debt to Book Value Regulus Therapeutics Inc RGLS|SYRS - Debt to Book Capital|Debts to Book Capitalization Telesis Bio, Inc.|TCON (traconpharma.com) - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Unity Biotechnology, Inc. (UBX)